• Home
  • Shop
  • About
  • FAQ
  • Contact
  • Compare Peptides
  • Wholesale
  • KPV – Research Compound Profile

    KPV – Research Compound Profile

    Category: Anti-Inflammatory Research | Molecular Type: Tripeptide (Lys-Pro-Val, MW ~342 Da) | Research Status: Preclinical (Extensive In Vitro & Animal Data)

    This page compiles published research data for qualified researchers. KPV is sold exclusively as a research compound, is not approved for human use, and this page does not constitute medical advice.

    Purchase for Research →

    Molecular Overview

    KPV (Lysine-Proline-Valine) is the C-terminal tripeptide fragment corresponding to residues 11–13 of alpha-melanocyte stimulating hormone (α-MSH), a 13-amino-acid neuropeptide produced by melanotrope cells in the pituitary gland. KPV represents the minimum amino acid sequence reported to retain the parent molecule’s anti-inflammatory activity in preclinical models without triggering melanocortin receptor–mediated skin pigmentation [1][2]. With a molecular weight of approximately 342 Da, KPV is among the smallest bioactive peptide fragments investigated in anti-inflammatory research.

    Preclinical data have demonstrated that nanomolar concentrations of KPV inhibit NF-κB and MAP kinase signaling pathways in cell culture, resulting in measurable reductions in pro-inflammatory cytokines including TNF-α, IL-6, IL-1β, and IL-8 across both intestinal epithelial and immune cell models [3][4]. Schiöth et al. (2006) reported that KPV demonstrated no binding affinity for MC1, MC3, or MC5 melanocortin receptors, distinguishing it mechanistically from the full-length α-MSH parent molecule [12].

    Mechanism of Action

    While full-length α-MSH mediates its effects primarily through melanocortin receptors (MC1R–MC5R), KPV’s anti-inflammatory activity operates through a fundamentally different mechanism. Dalmasso et al. (2008) demonstrated that KPV does not activate melanocortin receptors and does not increase intracellular cAMP—the hallmark signaling event of receptor engagement. Instead, KPV enters cells via the H⁺-coupled oligopeptide transporter PepT1 (SLC15A1), which exhibits a high affinity for KPV (K_m ~160 μM in intestinal epithelial cell culture), exceeding its reported affinity for most other di- and tripeptide substrates [3]. This transport mechanism has been noted in the literature as relevant to intestinal-inflammation research models, since PepT1 expression is reported to be upregulated in inflamed colonic epithelium and immune cells in preclinical inflammatory-bowel models [3][10].

    Once intracellular, KPV directly interferes with the activation of nuclear factor-kappa B (NF-κB), a key transcription factor governing inflammatory gene expression. Specifically, KPV is reported to reduce IκBα phosphorylation and degradation, thereby limiting NF-κB nuclear translocation and subsequent transcription of pro-inflammatory cytokines [3][4]. In parallel, KPV suppresses the phosphorylation of mitogen-activated protein kinases (MAPKs)—including ERK1/2, JNK, and p38—which represent a second major inflammatory signaling cascade [3]. The downstream consequence of this dual pathway inhibition described in the literature is a measurable reduction in the synthesis and secretion of key inflammatory mediators: IL-8, TNF-α, IL-6, IL-1β, IL-12, and IFN-γ [3][4][11].

    Land (2012) further demonstrated that KPV produces a concentration-dependent inhibition of NF-κB signaling and IL-8 release in human bronchial epithelial cell culture, extending the scope of KPV research beyond intestinal-cell models to airway-epithelium models [4]. Wang et al. (2019) provided a comprehensive review of melanocortin peptide anti-inflammatory signaling pathways, situating KPV within the broader landscape of melanocortin-mediated immune regulation research [18].

    A distinguishing structural feature of KPV relative to full-length α-MSH is the absence of reported melanogenic activity. Because KPV does not bind MC1R (the receptor associated with melanogenesis), published studies have not reported skin-pigmentation changes attributable to KPV [1][12]. This receptor-selectivity profile has been noted in the literature as distinguishing KPV from full-length melanocortin agonists for research purposes. Additionally, as a tripeptide of just three amino acids, KPV demonstrates in preclinical models greater apparent resistance to gastrointestinal enzymatic degradation compared to larger peptides, a property that has enabled investigation of oral administration in animal-model research designs [3].

    Published Research Parameters

    The following table indexes the study models, durations, and reported observations of selected peer-reviewed publications. Dose, frequency, and administration-route details are deliberately omitted. This is a bibliographic index only — not a protocol and not a recommendation for any use.

    Study / YearModelDurationKey ObservationReference
    Dalmasso et al., 2008Mouse (DSS-induced colitis)Duration of colitis inductionReduction in MPO activity; significant reduction in colonic IL-6, IL-12 mRNA[3]
    Dalmasso et al., 2008Mouse (TNBS-induced colitis)Duration of colitis inductionReduction in MPO activity; reduced TNF-α, IL-6, IL-1β, IFN-γ expression[3]
    Dalmasso et al., 2008Human intestinal epithelial cells (in vitro)Acute stimulation with IL-1βReduction in NF-κB–dependent luciferase activity and IκBα degradation[3]
    Land, 2012Human bronchial epithelial cells (in vitro)AcuteConcentration-dependent inhibition of NF-κB signaling and IL-8 release[4]
    Bonfiglio et al., 2006Rabbit (corneal wound model)Up to 60 hoursAccelerated corneal re-epithelization relative to untreated controls[14]
    Xiao et al., 2017Mouse (ulcerative colitis model)Multi-day treatment courseAccelerated mucosal healing and inflammation reduction; no significant toxicity signals[13]
    Viennois et al., 2016Mouse (colitis-associated cancer model)Chronic modelReduced carcinogenesis signal in colitis-associated cancer model[10]
    Getting et al., 2003In vitro / in vivo modelsVariableDissection of anti-inflammatory effects of KPV vs. core α-MSH sequence[11]

    Stability & Storage Characteristics

    Published literature and peptide manufacturer guidelines report the following stability data for KPV and related small peptides:

    • Lyophilized form: Lyophilized peptides demonstrate optimal long-term stability at temperatures of −20 °C or below. Short-term storage at 2–8 °C is acceptable for periods of weeks, though freezer storage is recommended for maximum shelf life [7].
    • Light sensitivity: Peptide solutions should be protected from direct light exposure, which accelerates degradation [7].
    • Gastric stability: Notably, KPV’s small size (3 amino acids, ~342 Da) is reported to confer relative resistance to gastrointestinal enzymatic degradation compared to larger peptide compounds, a property leveraged by Dalmasso et al. (2008) in an oral-administration preclinical colitis model [3].

    Analytical Characterization

    Research-grade KPV is characterized with an orthogonal analytical panel appropriate for a small tripeptide. Reverse-phase HPLC with UV detection at 214 nm resolves the intact tripeptide from free amino acids and truncated synthesis by-products; because KPV lacks an aromatic chromophore, detection relies on the peptide bond absorbance rather than a distinguishing side-chain signal. Electrospray mass spectrometry confirms the intact monoisotopic mass and readily distinguishes KPV from its hydrolysis products (free lysine, proline, and valine) given the small mass differences involved. Because the valine and proline residues are both chiral centers introduced during solid-phase synthesis, chiral HPLC or GC-MS analysis is used to verify stereochemical purity and detect racemization by-products, which are a more significant proportion-of-mass concern for very short peptides than for larger ones. Researchers should retain the available lot documentation for each lot.

    Key Published Research Findings

    NF-κB and MAPK Pathway Inhibition

    In a 2008 Gastroenterology study using human intestinal epithelial cells stimulated with IL-1β, Dalmasso et al. observed that KPV at nanomolar concentrations significantly reduced NF-κB–dependent luciferase activity and IκBα degradation, demonstrating intracellular anti-inflammatory signaling at low concentrations in cell culture [3]. Land (2012) corroborated these findings in human bronchial epithelial cells, reporting concentration-dependent inhibition of NF-κB signaling and IL-8 release, extending the observed effects beyond intestinal-cell models [4].

    Pro-Inflammatory Cytokine Modulation

    In DSS-induced colitis models, Dalmasso et al. (2008) documented that oral KPV administration decreased colonic IL-6, IL-12, IFN-γ, and IL-1β mRNA expression, with statistically significant reductions observed for IL-6 and IL-12. In the TNBS colitis model within the same study, KPV significantly reduced TNF-α, IL-6, IL-1β, and IFN-γ expression at the tissue level [3]. Getting et al. (2003) further dissected the anti-inflammatory properties of the C-terminal KPV sequence relative to the core α-MSH peptide, identifying KPV as an active anti-inflammatory moiety within the parent peptide [11].

    Colitis Models (Preclinical)

    Dalmasso et al. (2008) reported that oral KPV reduced myeloperoxidase (MPO) activity in both DSS-induced and TNBS-induced colitis mouse models, accompanied by histological improvement and preservation of colon length and weight in these preclinical models [3]. Xiao et al. (2017) subsequently demonstrated that KPV loaded into hyaluronic acid–functionalized nanoparticles achieved targeted oral delivery to inflamed colonic mucosa in mice, resulting in accelerated mucosal healing and inflammation reduction in a murine ulcerative colitis model [13]. These findings are limited to preclinical rodent models and have not been evaluated in controlled human studies.

    Corneal Wound Model (Preclinical)

    In a 2006 Experimental Eye Research study, Bonfiglio et al. reported that topical KPV application accelerated corneal re-epithelization in a rabbit wound model relative to untreated controls [14]. Böhm and Luger (2019) reviewed the broader preclinical wound-healing research literature on melanocortin peptides including KPV in cutaneous injury models [15]. These are preclinical animal-model findings and are not evidence of wound-treatment efficacy in humans.

    Antimicrobial Properties (In Vitro)

    Seo et al. (2012) reviewed synthetic KPV-based peptides and reported that the dimeric construct (CKPV)₂ demonstrated direct antimicrobial activity against Staphylococcus aureus and Candida albicans in vitro with low host cell toxicity in the same assays [16].

    Colitis-Associated Cancer Model (Preclinical)

    In a 2016 Cellular and Molecular Gastroenterology and Hepatology study, Viennois et al. reported that PepT1-mediated KPV administration reduced a carcinogenesis signal in a murine model of colitis-associated cancer, implicating both the anti-inflammatory mechanism and the PepT1 transport pathway as factors in the observed effect [10].

    Melanocortin Receptor Binding Profile

    Brzoska et al. (2008) and Luger and Brzoska (2007) reported that KPV, unlike full-length α-MSH, does not activate MC1R and consequently is not associated with the skin-pigmentation, appetite, or other receptor-mediated effects reported for full melanocortin receptor agonists [1][2]. Schiöth et al. (2006) confirmed the absence of measurable KPV binding to MC1, MC3, and MC5 receptors in binding assays [12].

    Regulatory Status

    • FDA approval: KPV has not been approved by the FDA for human use.
    • Clinical trial status: As of the current literature review, no registered human clinical trials for KPV monotherapy have been identified on ClinicalTrials.gov. Research remains at the preclinical stage.
    • Research compound classification: KPV is sold exclusively as a research compound for in vitro and preclinical investigation. It is not intended for human consumption or self-administration.
    • Broader regulatory context: Melanocortin-based peptides remain an active area of preclinical and pharmaceutical research generally, with several related compounds under investigation in the published literature.

    References

    1. Endocrine Reviews (2008) — Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. “α-Melanocyte-Stimulating Hormone and Related Tripeptides: Biochemistry, Antiinflammatory and Protective Effects In Vitro and In Vivo, and Future Perspectives for the Treatment of Immune-Mediated Inflammatory Diseases.” View Source

    2. Annals of the Rheumatic Diseases (2007) — Luger TA, Brzoska T. “α-MSH Related Peptides: A New Class of Anti-inflammatory and Immunomodulating Drugs.” View Source

    3. Gastroenterology (2008) — Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. “PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation.” View Source

    4. International Journal of Physiology, Pathophysiology and Pharmacology (2012) — Land SC. “Inhibition of Cellular and Systemic Inflammation Cues in Human Bronchial Epithelial Cells by Melanocortin-Related Peptides: Mechanism of KPV Action and a Role for MC3R Agonists.” View Source

    5. Bachem (Peptide Handling Guidelines) — “Handling and Storage Guidelines for Peptides: Long-Term Stability Best Achieved in Lyophilized Form at <−15 °C.” View Source

    6. Cellular and Molecular Gastroenterology and Hepatology (2016) — Viennois E, Ingersoll SA, Ayyadurai S, Zhao Y, Wang L, Zhang M, Han MK, Garg P, Merlin D. “Critical Role of PepT1 in Promoting Colitis-Associated Cancer and Therapeutic Benefits of the Anti-Inflammatory PepT1-Mediated Tripeptide KPV in a Murine Model.” View Source

    7. Journal of Pharmacology and Experimental Therapeutics (2003) — Getting SJ, Schiöth HB, Perretti M. “Dissection of the Anti-Inflammatory Effect of the Core and C-Terminal (KPV) α-Melanocyte-Stimulating Hormone Peptides.” View Source

    8. Basic & Clinical Pharmacology & Toxicology (2006) — Schiöth HB, Muceniece R, Mutule I, et al. “New Melanocortin 1 Receptor Binding Motif Based on the C-Terminal Sequence of α-Melanocyte-Stimulating Hormone.” View Source

    9. Molecular Therapy (2017) — Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D. “Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid–Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis.” View Source

    10. Experimental Eye Research (2006) — Bonfiglio V, Camillieri G, Avitabile T, Leggio GM, Drago F. “Effects of the COOH-Terminal Tripeptide α-MSH(11-13) on Corneal Epithelial Wound Healing: Role of Nitric Oxide.” View Source

    11. Experimental Dermatology (2019) — Böhm M, Luger TA. “Are Melanocortin Peptides Future Therapeutics for Cutaneous Wound Healing?” View Source

    12. Molecules (2012) — Seo MD, Won HS, Kim JH, Mishig-Ochir T, Lee BJ. “Antimicrobial Peptides for Therapeutic Applications: A Review.” View Source

    13. Frontiers in Endocrinology (2019) — Wang W, Guo DY, Lin YJ, Tao YX. “Melanocortin Regulation of Inflammation.” View Source


    ⚠️ Disclaimer: This page is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. KPV is sold exclusively as a research compound, has not been approved by the FDA for human consumption, and is not intended for human use or self-administration. All information is derived from published peer-reviewed literature. Research must comply with all applicable laws, regulations, and institutional guidelines.

    Purchase KPV for Research →